Evotec SE announced that the company has joined forces with the Crohn's & Colitis Foundation. Under the collaboration, Evotec joins forces with the Foundation's IBD Therapeutics Incubator programme that facilitates collaboration between the Foundation, academic researchers, and industry partners to translate groundbreaking basic research that was performed by academic researchers and identified by the Foundation into medical innovations for IBD patients. The collaboration leverages Evotec's end-to-end integrated R&D platform to advance drug discovery for two innovative drug targets that address major unmet medical needs of patients with Crohn's disease and ulcerative colitis: Fibrosis, the excessive accumulation of scar tissue in the intestinal wall, and impaired intestinal barrier function, which leads to increased intestinal permeability, also known as leaky gut.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.72 EUR | +0.15% |
|
+8.30% | -54.32% |
03/07 | EVOTEC : RBC reiterates its Buy rating | ZD |
01/07 | Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.32% | 1.87B | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- EVT Stock
- News Evotec SE
- Evotec SE and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies